Dyno Therapeutics announced on April 27, 2026, that it will present new capsids and AI advancements in gene delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.234
The company specializes in using AI to engineer AAV capsids for improved in vivo gene delivery to targets like eye, muscle, brain, and CNS.123
This follows recent milestones, including Astellas exercising a license for a skeletal muscle-targeted AAV capsid in 2026 and prior CNS license by Roche in January 2025.2
Dyno has a history of ASGCT presentations, such as in 2024 for AI methods in AAV capsid design.14
Sources:
1. https://www.biospace.com/dyno-therapeutics-to-present-on-breakthroughs-in-ai-methods-for-aav-capsid-design-at-asgct-annual-congress-and-synbiobeta-global-synthetic-biology-conference
2. https://www.businesswire.com/news/home/20260408079855/en/Dyno-Therapeutics-Announces-Capsid-License-Exercised-by-Astellas-for-Skeletal-Muscle-Targeted-Gene-Delivery-Validating-AI-Powered-Technology-for-Biological-Sequence-Design